Moderna to Present at Upcoming Investor Conferences in December 2021

Rhea-AI Summary

Moderna (NASDAQ: MRNA), a leader in messenger RNA therapeutics, has announced its participation in two upcoming virtual investor conferences on December 1. The NASDAQ 45^th Investor Conference will take place at 9:30 a.m. ET, followed by the Piper Sandler 33^rd Annual Virtual Healthcare Conference at 2:00 p.m. ET. Investors can access live webcasts of both presentations on Moderna's website, where replays will also be available for 30 days. Moderna has significantly advanced in mRNA science, especially in developing COVID-19 vaccines.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming virtual investor conferences:

• NASDAQ 45^th Investor Conference on Wednesday, December 1^st at 9:30 a.m. ET
• Piper Sandler 33^rd Annual Virtual Healthcare Conference on Wednesday, December 1^st at 2:00 p.m. ET

A live webcast of each presentation will be available under “Events and Presentations” in the Investors section of the Moderna website at investors.modernatx.com. A replay of each webcast will be archived on Moderna’s website for at least 30 days following the presentation.

About Moderna

In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.

Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211122006214/en/

Investors:

Lavina Talukdar

Senior Vice President & Head of Investor Relations

617-209-5834

Lavina.Talukdar@modernatx.com

Source: Moderna, Inc.

FAQ

What dates is Moderna participating in investor conferences?

Moderna is participating in two investor conferences on December 1.

What time is Moderna's presentation at the NASDAQ 45th Investor Conference?

Moderna's presentation at the NASDAQ 45th Investor Conference is scheduled for 9:30 a.m. ET.

What time is Moderna's presentation at the Piper Sandler Annual Healthcare Conference?

Moderna's presentation at the Piper Sandler 33rd Annual Healthcare Conference is at 2:00 p.m. ET.

Where can I watch the live webcasts of Moderna's presentations?

The live webcasts of Moderna's presentations can be accessed on their website.

How long will the replay of Moderna's presentations be available?

Replays of Moderna's presentations will be available for at least 30 days after the events.

What is Moderna's focus in the biotechnology field?

Moderna focuses on developing messenger RNA (mRNA) therapeutics and vaccines.